ArticleJournal of natural medicines2023
Three new meroterpenoids from Sargassum macrocarpum and their inhibitory activity against amyloid β aggregation.
Article in Journal of natural medicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Four Undescribed Chromane-Type Meroterpenoids From Sargassum siliquastrum and Their Inhibitory Activity Against Amyloid-β42 Aggregation.Chemistry & biodiversity · 2026Article
- New meroterpenoids from Sargassum macrocarpum as inhibitors of amyloid β aggregation.Journal of natural medicines · 2026Article
- Seven undescribed meroterpenoids from Sargassum siliquastrum and their inhibitory activity against amyloid β aggregation.Journal of natural medicines · 2025Article
- A Narrative Review on the Neuroprotective Potential of Brown Macroalgae in Alzheimer's Disease.Nutrients · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Amyloid β (Aβ) is thought to be involved in the pathogenesis of Alzheimer's disease (AD). Aβ aggregation in the brain is considered the cause of AD. Therefore, inhibiting Aβ aggregation and degrading existing Aβ aggregates is a promising approach for the treatment and prevention of the disease. In searching for inhibitors of Aβ42 aggregation, we found that meroterpenoids isolated from Sargassum macrocarpum possess potent inhibitory activities. Therefore, we searched for active compounds from this brown alga and isolated 16 meroterpenoids, which contain three new compounds. The structures of these new compounds were elucidated using two-dimensional nuclear magnetic resonance techniques. Thioflavin-T assay and transmission electron microscopy were used to reveal the inhibitory activity of these compounds against Aβ42 aggregation. All the isolated meroterpenoids were found to be active, and compounds with a hydroquinone structure tended to have stronger activity than those with a quinone structure.
Indexed as
Identifiers
36933089What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.